Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/2230-8210.196016 http://scihub22266oqcxt.onion/10.4103/2230-8210.196016 28217522!5240065!28217522     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28217522&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Indian+J+Endocrinol+Metab 2017 ; 21 (1): 196-209 Nephropedia Template TP {{tp|p=28217522|t=2017. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus |pdf=|usr=}}{{28217522}} gab.com Text A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus JO: Indian J Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=28217522 #FOAvip Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic armamentarium of glucose-lowering drugs. This review summarizes findings from different clinical and observational studies of canagliflozin 300 mg in patients with type 2 diabetes mellitus (T2DM). By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose, thereby increasing urinary glucose excretion in patients with T2DM. Canagliflozin 300 mg has been shown to be effective in lowering glycated hemoglobin, fasting plasma glucose, and postprandial glucose in patients with T2DM. Canagliflozin 300 mg also demonstrated significant reductions in body weight and blood pressure and has a low risk of causing hypoglycemia, when not used in conjunction with insulin and insulin secretagogues. Canagliflozin 300 mg was generally well tolerated in clinical studies. The most frequently reported adverse events include genital mycotic infections, urinary tract infections, osmotic diuresis, and volume depletion-related events. Twit Text FOAVip A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus ????Indian J Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=28217522 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28217522 #FOAvip English Wikipedia <ref>{{Cite pmid|28217522}}</ref> A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus #MMPMID28217522 Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S Indian J Endocrinol Metab 2017[Jan]; 21 (1): 196-209 PMID28217522show ga Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic armamentarium of glucose-lowering drugs. This review summarizes findings from different clinical and observational studies of canagliflozin 300 mg in patients with type 2 diabetes mellitus (T2DM). By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose, thereby increasing urinary glucose excretion in patients with T2DM. Canagliflozin 300 mg has been shown to be effective in lowering glycated hemoglobin, fasting plasma glucose, and postprandial glucose in patients with T2DM. Canagliflozin 300 mg also demonstrated significant reductions in body weight and blood pressure and has a low risk of causing hypoglycemia, when not used in conjunction with insulin and insulin secretagogues. Canagliflozin 300 mg was generally well tolerated in clinical studies. The most frequently reported adverse events include genital mycotic infections, urinary tract infections, osmotic diuresis, and volume depletion-related events. ?A review of clinical efficacy and safety of canagliflozin 300 mg in th(epmc).pdf DeepDyve Pubget Overpricing